See today's BioWorld Asia
To read the full story, subscribe or sign in.

Gennbio licenses in two immunosuppressants valued up to $164M from Genexine

Jan. 14, 2020
By Jihyun Kim
Gennbio Co. Ltd. has signed an agreement with fellow Korean biotech Genexine Inc. to in-license two immunosuppressant drug candidates called GX-P1 (PD-L1 hyfc) and BSF-110 (PD-L1-hyFc-1L10m).
BioWorld Asia Deals and M&A Immune Asia-Pacific